Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Treatment of osteoarthritis

Study results show strengthening of total cartilage thickness

    • General Internal Medicine
    • Market & Medicine
    • Rheumatology
    • RX
    • Studies
  • 3 minute read

Approximately 237 million people worldwide are affected by symptomatic and activity-limiting osteoarthritis (OA). Among disabling conditions, OA has the third fastest growth, with the knee joint being the most commonly affected. Currently, OA therapies predominantly treat symptoms and there are no approved drugs to prevent or delay disease progression.

Symptomatic knee joint arthrosis is associated with physical disability, reduced quality of life, and increased mortality in the elderly [3,4]. In the final stage of the disease, knee replacement is often necessary. FORWARD (FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses) was a five-year, multicenter, randomized, phase II dose-finding study of sprifermin, a recombinant human fibroblast growth factor 18, in patients with symptomatic, radiologically confirmed knee osteoarthritis.

The primary endpoint of the study, which included 549 patients, was the change in total cartilage thickness in the femorotibial joint on quantitative MRI compared with baseline after two years with sprifermin. This endpoint was met: at the two-year treatment time point, there was a mean increase in total cartilage thickness in the two highest-dose sprifermin groups compared with the placebo group. In the groups receiving 100 µg of sprifermin as an intra-articular injection, the statistically significant increase in total cartilage thickness was +0.05 mm (injection every 6 months; 95% CI 0.03-0.07) and +0.04 mm (injection every 12 months; 95% CI 0.03-0.07), respectively, compared with placebo. The change in cartilage thickness after two years of treatment with sprifermin at a dose of 30 µg every 6 or 12 months showed no significant differences compared to placebo.

The most common adverse events (AEs) included skeletal muscle and connective tissue disorders (arthralgia, back pain), infections and parasitic diseases (upper respiratory tract infection, nasopharyngitis), vascular disorders (hypertension), and nervous system disorders (headache). However, they were predominantly of mild or moderate severity.

An exploratory post-hoc analysis presented in November at the American College of Rheumatology (ACR) Annual Meeting additionally evaluated cartilage thickness changes and symptomatic treatment outcomes in a subgroup of OA patients who had both more severe pain and reduced cartilage thickness at baseline, as measured by joint space width, and an increased risk of structural and symptomatic progression. In this “at risk” subgroup, WOMAC scores continued to improve over the 3-year period and were significantly in favor of sprifermin at year 3 (18 months after the last injection) compared with placebo (mean difference in WOMAC pain scores for sprifermin 100 µg every 6 months compared with placebo: -8.75 [95% CI: -22.42, 4.92]). These results support further testing of sprifermin as a potential OA therapy in higher-risk patient populations.

Source: Merck

 

Literature:

  1. GBD Collaborators, et al: Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1545-1602.
  2. Osteoarthritis Research Society International. Osteoarthritis: a serious disease. www.oarsi.org/sites/default/files/docs/2016/oarsi_white_paper_oa-serious-disease.pdf [abgerufen im September 2019]
  3. Cross M, Smith E, Hoy D, et al: The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014; 73(7): 1323-1330.
  4. Nuesch E, Dieppe P, et al: All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ 2011; 342: d1165

 

InFo PAIN & GERIATURE 2019; 1(1): 38.

Related Topics
  • Femorotibial joint
  • Knee joint arthroplasty
  • Osteoarthritis
  • Rheumatism
Previous Article
  • Dupilumab

EU approval for severe chronic rhinosinusitis with polyposis nasi

  • General Internal Medicine
  • Market & Medicine
  • ORL
  • RX
View Post
Next Article
  • Guselkumab

High response rate maintained over 4 years

  • Dermatology and venereology
  • Market & Medicine
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 7 min
  • Diabetes-related cardiovascular diseases

Ferroptosis: key mechanisms and novel therapeutic approaches

    • Cardiology
    • Education
    • Endocrinology and Diabetology
    • Hematology
    • RX
    • Studies
View Post
  • 4 min
  • Atrial fibrillation

What’s new with the “pace-and-ablate” strategy?

    • Cardiology
    • Congress Reports
    • General Internal Medicine
    • RX
    • Studies
View Post
  • 3 min
  • De-escalation strategies

De-escalation strategies – less is more

    • Congress Reports
    • Oncology
    • Pneumology
    • Prevention and health care
    • RX
View Post
  • 5 min
  • Pathogens in the brain

When infections trigger strokes

    • Education
    • General Internal Medicine
    • Infectiology
    • Neurology
    • Prevention and health care
    • RX
    • Studies
    • Tropical and travel medicine
View Post
  • 15 min
  • Pulmonary hypertension

PH and lung diseases

    • Cardiology
    • CME continuing education
    • Pneumology
    • RX
    • Studies
View Post
  • 15 min
  • Diabetes mellitus

Treatment of comorbidities in older people

    • Cardiology
    • CME continuing education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Geriatrics
    • RX
View Post
  • 0 min
  • Advanced NSCLC

MARIPOSA: Combination therapy as the new standard of care for EGFR-mutated NSCLC

    • Congress Reports
    • Oncology
    • Pneumology
    • RX
    • Studies
View Post
  • 7 min
  • Atopic dermatitis and allergies Atopic dermatitis and allergies

Type 2 inflammation and other factors

    • Allergology and clinical immunology
    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • Dermatology and venereology
    • Congress Reports
    • RX
    • RX
    • Studies
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    PH and lung diseases
  • 2
    Treatment of comorbidities in older people
  • 3
    Multidisciplinary teams in oncology
  • 4
    Colorectal cancer screening – an update
  • 5
    Constant dripping – alcohol and cancer

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.